United States Biotechnology & Medical Research

Mereo BioPharma Group PLC (MREO)

Track

Track

Ticker: MREO Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Mereo BioPharma Group PLC. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.8
Sermon Charles General Counsel Officer
Transaction date
Sale
Price
441.53
Quantity 8,957 -4.4%
Value US$3,254,945
1.8
Fox Christine Ann Chief Financial Officer Officer
Transaction date
Sale
Price
379.96
Quantity 6,587 +27.2%
Value US$3,612,096
1.8
Lewicki John A. Chief Scientific Officer Officer
Transaction date
Sale
Price
171.74
Quantity 97,745 +11.5%
Value US$832,427
1.8
Scots-Knight Denise Chief Executive Officer Executive Director
Transaction date
Sale
Price
4.22
Quantity 60,046 -6.9%
Value US$253,454
2.2
Hughes-Wilson Alexandra See Remarks Officer
Transaction date
Sale
Price
4.22
Quantity 84,008 -62.5%
Value US$354,598
2.2
Hughes-Wilson Alexandra See Remarks Officer
Transaction date
Sale
Price
4.22
Quantity 16,304 -10.8%
Value US$68,819
1.8
Sermon Charles General Counsel Officer
Transaction date
Sale
Price
4.47
Quantity 9,980 -4.0%
Value US$44,638
1.8
Fox Christine Ann Chief Financial Officer Officer
Transaction date
Sale
Price
4.47
Quantity 9,128 -7.8%
Value US$40,827
1.8
Lewicki John A. Chief Scientific Officer Officer
Transaction date
Sale
Price
4.47
Quantity 5,212 -5.5%
Value US$23,312
1.8
Scots-Knight Denise Chief Executive Officer Executive Director
Transaction date
Sale
Price
4.47
Quantity 28,611 -3.2%
Value US$127,968
2.2
Hughes-Wilson Alexandra See Remarks Officer
Transaction date
Sale
Price
4.47
Quantity 40,029 -21.0%
Value US$179,038
2.2
Hughes-Wilson Alexandra See Remarks Officer
Transaction date
Sale
Price
4.47
Quantity 7,769 -3.9%
Value US$34,748
1.8
Scots-Knight Denise Officer; Director Executive Director
Transaction date
Proposed sale
Price
4.66
Quantity 88,657
Value US$413,142
1.8
Lewicki John A. Officer Officer
Transaction date
Proposed sale
Price
4.66
Quantity 16,149
Value US$75,254
2.2
Alexandra Hughes-Wilson Officer Officer
Transaction date
Proposed sale
Price
4.66
Quantity 148,110
Value US$690,193
1.8
Sermon Charles Officer Officer
Transaction date
Proposed sale
Price
4.66
Quantity 30,926
Value US$144,115
1.8
Fox Christine Ann Officer Officer
Transaction date
Proposed sale
Price
4.66
Quantity 28,286
Value US$131,813
4.0
PAKIANATHAN DEEPIKA Non-Executive Director
Transaction date
Sale
Price
4.43
Quantity 105,244 -100.0%
Value US$466,210
4.0
Deepika Pakianathan Director Non-Executive Director
Transaction date
Proposed sale
Price
4.43
Quantity 105,244
Value US$466,210
1.8
Sermon Charles General Counsel Officer
Transaction date
Sale
Price
3.39
Quantity 32,187 -14.9%
Value US$109,217
1.8
Lewicki John A. Chief Scientific Officer Officer
Transaction date
Sale
Price
3.39
Quantity 16,808 -25.6%
Value US$57,033
2.2
Hughes-Wilson Alexandra See Remarks Officer
Transaction date
Sale
Price
3.39
Quantity 22,968 -39.9%
Value US$77,935
1.8
Fox Christine Ann Chief Financial Officer Officer
Transaction date
Sale
Price
3.39
Quantity 29,439 -33.8%
Value US$99,892
1.8
Scots-Knight Denise Chief Executive Officer Executive Director
Transaction date
Sale
Price
3.39
Quantity 92,273 -11.5%
Value US$313,101
1.8
Sermon Charles General Counsel Officer
Transaction date
Sale
Price
3.69
Quantity 14,202 -6.2%
Value US$52,461
1.8
Lewicki John A. Chief Scientific Officer Officer
Transaction date
Sale
Price
3.69
Quantity 7,416 -10.2%
Value US$27,394
2.2
Hughes-Wilson Alexandra See Remarks Officer
Transaction date
Sale
Price
3.69
Quantity 10,134 -15.0%
Value US$37,434
1.8
Fox Christine Ann Chief Financial Officer Officer
Transaction date
Sale
Price
3.69
Quantity 12,990 -13.0%
Value US$47,984
1.8
Scots-Knight Denise Chief Executive Officer Executive Director
Transaction date
Sale
Price
3.69
Quantity 40,712 -4.8%
Value US$150,386
1.8
Lewicki John A. Officer Officer
Transaction date
Proposed sale
Price
3.98
Quantity 26,647
Value US$106,055
1.8
Scots-Knight Denise Officer; Director Executive Director
Transaction date
Proposed sale
Price
3.98
Quantity 146,284
Value US$582,210
2.2
Alexandra Hughes-Wilson Officer Officer
Transaction date
Proposed sale
Price
3.98
Quantity 33,102
Value US$131,746
1.8
Sermon Charles Officer Officer
Transaction date
Proposed sale
Price
3.98
Quantity 51,028
Value US$203,091
1.8
Fox Christine Ann Officer Officer
Transaction date
Proposed sale
Price
3.98
Quantity 46,672
Value US$185,755
2.2
Alexandra Hughes-Wilson Officer Officer
Transaction date
Proposed sale
Price
3.98
Quantity 33,102
Value US$131,746
1.8
Sermon Charles Officer Officer
Transaction date
Proposed sale
Price
3.98
Quantity 51,028
Value US$203,091
1.8
Fox Christine Ann Officer Officer
Transaction date
Proposed sale
Price
3.98
Quantity 46,672
Value US$185,755
1.8
Scots-Knight Denise Officer; Director Executive Director
Transaction date
Proposed sale
Price
3.98
Quantity 146,284
Value US$582,210
1.8
Lewicki John A. Officer Officer
Transaction date
Proposed sale
Price
3.98
Quantity 26,647
Value US$106,055
2.2
Alexandra Hughes-Wilson Officer Officer
Transaction date
Proposed sale
Price
2.96
Quantity 100,432
Value US$297,506
2.2
Hughes-Wilson Alexandra See Remarks Officer
Transaction date
Sale
Price
2.94
Quantity 50,082 -60.6%
Value US$147,241
2.2
Hughes-Wilson Alexandra See Remarks Officer
Transaction date
Sale
Price
2.99
Quantity 50,350 -46.2%
Value US$150,546
1.8
Charles Sermon General Counsel
Transaction date
Purchase
Price
2.41
Quantity 18,405
Value US$44,356
John Richard Head of Corporate Development Officer
Transaction date
Purchase
Price
2.36
Quantity 6,496
Value US$15,330
Brian Schwartz Non-Executive Director Executive Director
Transaction date
Purchase
Price
2.35
Quantity 20,029
Value US$47,068
1.8
Denise Scots-Knight Chief Executive Officer Officer
Transaction date
Purchase
Price
2.36
Quantity 30,044
Value US$70,903
John Richard Head of Corporate Development Officer
Transaction date
Purchase
Price
2.76
Quantity 3,500
Value US$9,660
1.8
Denise Scots-Knight Chief Executive Officer Officer
Transaction date
Purchase
Price
2.85
Quantity 10,563
Value US$30,105
John Richard Head of Corporate Development Officer
Transaction date
Purchase
Price
2.20
Quantity 3,500
Value US$7,704
2.5
Richard Jones Chief Financial Officer Officer
Transaction date
Purchase
Price
0.38
Quantity 26,100
Value £9,892
2.5
Richard Jones Chief Financial Officer Officer
Transaction date
Purchase
Price
0.38
Quantity 25,440
Value £9,667
2.1
Anders Ekblom non-executive Director Executive Director
Transaction date
Purchase
Price
2.54
Quantity 10,000
Value US$25,400
Alastair Mackinnon Chief Medical Officer Officer
Transaction date
Purchase
Price
2.60
Quantity 4,930
Value US$12,818
Alastair Mackinnon Chief Medical Officer Officer
Transaction date
Purchase
Price
0.39
Quantity 12,879
Value £4,971
Alastair Mackinnon Chief Medical Officer Officer
Transaction date
Purchase
Price
3.29
Quantity 365
Value US$1,201
Alastair Mackinnon Chief Medical Officer Officer
Transaction date
Purchase
Price
0.59
Quantity 15,169
Value £8,980
John Richard Head of Corporate Development Officer
Transaction date
Purchase
Price
2.96
Quantity 1,500
Value US$4,437
Alastair MacKinnon Chief Medical Officer Officer
Transaction date
Purchase
Price
0.60
Quantity 3,313
Value £1,988
Alastair MacKinnon Chief Medical Officer Officer
Transaction date
Purchase
Price
0.61
Quantity 1,631
Value £995
Alastair MacKinnon Chief Medical Officer Officer
Transaction date
Purchase
Price
0.57
Quantity 800
Value £456
1.8
Denise Scots-Knight Chief Executive Officer Officer
Transaction date
Purchase
Price
0.59
Quantity 13,500
Value £7,965
1.8
Denise Scots-Knight Chief Executive Officer Officer
Transaction date
Purchase
Price
0.54
Quantity 6,000
Value £3,210
John Richard Head of Corporate Development Officer
Transaction date
Purchase
Price
3.31
Quantity 1,500
Value US$4,970
1.8
Denise Scots-Knight Chief Executive Officer Officer
Transaction date
Purchase
Price
0.54
Quantity 6,000
Value £3,240
1.8
Charles Sermon General Counsel
Transaction date
Purchase
Price
0.54
Quantity 6,355
Value £3,400
1.8
Charles Sermon General Counsel
Transaction date
Purchase
Price
3.11
Quantity 754
Value £2,341
1.8
Charles Sermon General Counsel
Transaction date
Purchase
Price
3.09
Quantity 590
Value US$1,821
Peter Bains Director Executive Director
Transaction date
Purchase
Price
0.42
Quantity 47,500
Value £19,950
1.8
Denise Scots-Knight Chief Executive Officer Officer
Transaction date
Purchase
Price
2.55
Quantity 2,000
Value £5,100
1.8
Denise Scots-Knight Chief Executive Officer Officer
Transaction date
Purchase
Price
0.45
Quantity 8,000
Value £3,600
1.8
Denise Scots-Knight Chief Executive Officer Officer
Transaction date
Purchase
Price
2.59
Quantity 2,000
Value £5,180
1.8
Denise Scots-Knight Chief Executive Officer Officer
Transaction date
Purchase
Price
0.45
Quantity 2,000
Value £900
John Richard Head of Corporate Development Officer
Transaction date
Purchase
Price
4.90
Quantity 3,000
Value US$14,709
Peter Bains Director Executive Director
Transaction date
Purchase
Price
4.92
Quantity 778
Value US$3,828
Peter Bains Director Executive Director
Transaction date
Purchase
Price
0.90
Quantity 47,500
Value £42,750
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-09-16 2024-09-13 S Sale
1.8
Sermon Charles

General Counsel

Officer
8,957 -4.4%
441.53
US$3,254,945 		8,957 -4.4% 441.53 US$3,254,945
2024-09-16 2024-09-13 S Sale
1.8
Fox Christine Ann

Chief Financial Officer

Officer
6,587 +27.2%
379.96
US$3,612,096 		6,587 +27.2% 379.96 US$3,612,096
2024-09-16 2024-09-13 S Sale
1.8
Lewicki John A.

Chief Scientific Officer

Officer
97,745 +11.5%
171.74
US$832,427 		97,745 +11.5% 171.74 US$832,427
2024-09-16 2024-09-13 S Sale
1.8
Scots-Knight Denise

Chief Executive Officer

Executive Director
60,046 -6.9%
4.22
US$253,454 		60,046 -6.9% 4.22 US$253,454
2024-09-16 2024-09-13 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
84,008 -62.5%
4.22
US$354,598 		84,008 -62.5% 4.22 US$354,598
2024-09-16 2024-09-13 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
16,304 -10.8%
4.22
US$68,819 		16,304 -10.8% 4.22 US$68,819
2024-09-16 2024-09-12 S Sale
1.8
Sermon Charles

General Counsel

Officer
9,980 -4.0%
4.47
US$44,638 		9,980 -4.0% 4.47 US$44,638
2024-09-16 2024-09-12 S Sale
1.8
Fox Christine Ann

Chief Financial Officer

Officer
9,128 -7.8%
4.47
US$40,827 		9,128 -7.8% 4.47 US$40,827
2024-09-16 2024-09-12 S Sale
1.8
Lewicki John A.

Chief Scientific Officer

Officer
5,212 -5.5%
4.47
US$23,312 		5,212 -5.5% 4.47 US$23,312
2024-09-16 2024-09-12 S Sale
1.8
Scots-Knight Denise

Chief Executive Officer

Executive Director
28,611 -3.2%
4.47
US$127,968 		28,611 -3.2% 4.47 US$127,968
2024-09-16 2024-09-12 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
40,029 -21.0%
4.47
US$179,038 		40,029 -21.0% 4.47 US$179,038
2024-09-16 2024-09-12 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
7,769 -3.9%
4.47
US$34,748 		7,769 -3.9% 4.47 US$34,748
2024-09-12 2024-09-12 PrS Proposed sale
1.8
Scots-Knight Denise

Officer; Director

Executive Director
88,657
4.66
US$413,142 		88,657 4.66 US$413,142
2024-09-12 2024-09-12 PrS Proposed sale
1.8
Lewicki John A.

Officer

Officer
16,149
4.66
US$75,254 		16,149 4.66 US$75,254
2024-09-12 2024-09-12 PrS Proposed sale
2.2
Alexandra Hughes-Wilson

Officer

Officer
148,110
4.66
US$690,193 		148,110 4.66 US$690,193
2024-09-12 2024-09-12 PrS Proposed sale
1.8
Sermon Charles

Officer

Officer
30,926
4.66
US$144,115 		30,926 4.66 US$144,115
2024-09-12 2024-09-12 PrS Proposed sale
1.8
Fox Christine Ann

Officer

Officer
28,286
4.66
US$131,813 		28,286 4.66 US$131,813
2024-08-23 2024-08-22 S Sale
4.0
PAKIANATHAN DEEPIKA
Non-Executive Director
105,244 -100.0%
4.43
US$466,210 		105,244 -100.0% 4.43 US$466,210
2024-08-22 2024-08-22 PrS Proposed sale
4.0
Deepika Pakianathan

Director

Non-Executive Director
105,244
4.43
US$466,210 		105,244 4.43 US$466,210
2024-06-27 2024-06-26 S Sale
1.8
Sermon Charles

General Counsel

Officer
32,187 -14.9%
3.39
US$109,217 		32,187 -14.9% 3.39 US$109,217
2024-06-27 2024-06-26 S Sale
1.8
Lewicki John A.

Chief Scientific Officer

Officer
16,808 -25.6%
3.39
US$57,033 		16,808 -25.6% 3.39 US$57,033
2024-06-27 2024-06-26 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
22,968 -39.9%
3.39
US$77,935 		22,968 -39.9% 3.39 US$77,935
2024-06-27 2024-06-26 S Sale
1.8
Fox Christine Ann

Chief Financial Officer

Officer
29,439 -33.8%
3.39
US$99,892 		29,439 -33.8% 3.39 US$99,892
2024-06-27 2024-06-26 S Sale
1.8
Scots-Knight Denise

Chief Executive Officer

Executive Director
92,273 -11.5%
3.39
US$313,101 		92,273 -11.5% 3.39 US$313,101
2024-06-27 2024-06-25 S Sale
1.8
Sermon Charles

General Counsel

Officer
14,202 -6.2%
3.69
US$52,461 		14,202 -6.2% 3.69 US$52,461
2024-06-27 2024-06-25 S Sale
1.8
Lewicki John A.

Chief Scientific Officer

Officer
7,416 -10.2%
3.69
US$27,394 		7,416 -10.2% 3.69 US$27,394
2024-06-27 2024-06-25 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
10,134 -15.0%
3.69
US$37,434 		10,134 -15.0% 3.69 US$37,434
2024-06-27 2024-06-25 S Sale
1.8
Fox Christine Ann

Chief Financial Officer

Officer
12,990 -13.0%
3.69
US$47,984 		12,990 -13.0% 3.69 US$47,984
2024-06-27 2024-06-25 S Sale
1.8
Scots-Knight Denise

Chief Executive Officer

Executive Director
40,712 -4.8%
3.69
US$150,386 		40,712 -4.8% 3.69 US$150,386
2024-06-24 2024-06-25 PrS Proposed sale
1.8
Lewicki John A.

Officer

Officer
26,647
3.98
US$106,055 		26,647 3.98 US$106,055
2024-06-24 2024-06-25 PrS Proposed sale
1.8
Scots-Knight Denise

Officer; Director

Executive Director
146,284
3.98
US$582,210 		146,284 3.98 US$582,210
2024-06-24 2024-06-25 PrS Proposed sale
2.2
Alexandra Hughes-Wilson

Officer

Officer
33,102
3.98
US$131,746 		33,102 3.98 US$131,746
2024-06-24 2024-06-25 PrS Proposed sale
1.8
Sermon Charles

Officer

Officer
51,028
3.98
US$203,091 		51,028 3.98 US$203,091
2024-06-24 2024-06-25 PrS Proposed sale
1.8
Fox Christine Ann

Officer

Officer
46,672
3.98
US$185,755 		46,672 3.98 US$185,755
2024-06-20 2024-06-21 PrS Proposed sale
2.2
Alexandra Hughes-Wilson

Officer

Officer
33,102
3.98
US$131,746 		33,102 3.98 US$131,746
2024-06-20 2024-06-21 PrS Proposed sale
1.8
Sermon Charles

Officer

Officer
51,028
3.98
US$203,091 		51,028 3.98 US$203,091
2024-06-20 2024-06-21 PrS Proposed sale
1.8
Fox Christine Ann

Officer

Officer
46,672
3.98
US$185,755 		46,672 3.98 US$185,755
2024-06-20 2024-06-21 PrS Proposed sale
1.8
Scots-Knight Denise

Officer; Director

Executive Director
146,284
3.98
US$582,210 		146,284 3.98 US$582,210
2024-06-20 2024-06-21 PrS Proposed sale
1.8
Lewicki John A.

Officer

Officer
26,647
3.98
US$106,055 		26,647 3.98 US$106,055
2024-05-23 2024-05-22 PrS Proposed sale
2.2
Alexandra Hughes-Wilson

Officer

Officer
100,432
2.96
US$297,506 		100,432 2.96 US$297,506
2024-05-23 2024-05-22 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
50,082 -60.6%
2.94
US$147,241 		50,082 -60.6% 2.94 US$147,241
2024-05-23 2024-05-22 S Sale
2.2
Hughes-Wilson Alexandra

See Remarks

Officer
50,350 -46.2%
2.99
US$150,546 		50,350 -46.2% 2.99 US$150,546
2020-10-12 2020-10-09 B Purchase
1.8
Charles Sermon

General Counsel
18,405
2.41
US$44,356 		18,405 2.41 US$44,356
2020-10-09 2020-10-07 B Purchase John Richard

Head of Corporate Development

Officer
6,496
2.36
US$15,330 		6,496 2.36 US$15,330
2020-10-09 2020-10-07 B Purchase Brian Schwartz

Non-Executive Director

Executive Director
20,029
2.35
US$47,068 		20,029 2.35 US$47,068
2020-10-09 2020-10-07 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
30,044
2.36
US$70,903 		30,044 2.36 US$70,903
2020-08-14 2020-08-12 B Purchase John Richard

Head of Corporate Development

Officer
3,500
2.76
US$9,660 		3,500 2.76 US$9,660
2020-08-05 2020-07-31 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
10,563
2.85
US$30,105 		10,563 2.85 US$30,105
2019-12-03 2019-12-02 B Purchase John Richard

Head of Corporate Development

Officer
3,500
2.20
US$7,704 		3,500 2.20 US$7,704
2019-11-27 2019-11-26 B Purchase
2.5
Richard Jones

Chief Financial Officer

Officer
26,100
0.38
£9,892 		26,100 0.38 £9,892
2019-11-25 2019-11-25 B Purchase
2.5
Richard Jones

Chief Financial Officer

Officer
25,440
0.38
£9,667 		25,440 0.38 £9,667
2019-11-22 2019-11-22 B Purchase
2.1
Anders Ekblom

non-executive Director

Executive Director
10,000
2.54
US$25,400 		10,000 2.54 US$25,400
2019-11-20 2019-11-19 B Purchase
Alastair Mackinnon

Chief Medical Officer

Officer
4,930
2.60
US$12,818 		4,930 2.60 US$12,818
2019-11-20 2019-11-19 B Purchase
Alastair Mackinnon

Chief Medical Officer

Officer
12,879
0.39
£4,971 		12,879 0.39 £4,971
2019-11-22 2019-10-04 B Purchase
Alastair Mackinnon

Chief Medical Officer

Officer
365
3.29
US$1,201 		365 3.29 US$1,201
2019-11-22 2019-10-04 B Purchase
Alastair Mackinnon

Chief Medical Officer

Officer
15,169
0.59
£8,980 		15,169 0.59 £8,980
2019-10-02 2019-09-30 B Purchase John Richard

Head of Corporate Development

Officer
1,500
2.96
US$4,437 		1,500 2.96 US$4,437
2019-09-26 2019-09-25 B Purchase
Alastair MacKinnon

Chief Medical Officer

Officer
3,313
0.60
£1,988 		3,313 0.60 £1,988
2019-09-25 2019-09-24 B Purchase
Alastair MacKinnon

Chief Medical Officer

Officer
1,631
0.61
£995 		1,631 0.61 £995
2019-09-24 2019-09-20 B Purchase
Alastair MacKinnon

Chief Medical Officer

Officer
800
0.57
£456 		800 0.57 £456
2019-09-20 2019-09-19 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
13,500
0.59
£7,965 		13,500 0.59 £7,965
2019-08-16 2019-08-16 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
6,000
0.54
£3,210 		6,000 0.54 £3,210
2019-08-16 2019-08-15 B Purchase John Richard

Head of Corporate Development

Officer
1,500
3.31
US$4,970 		1,500 3.31 US$4,970
2019-08-16 2019-08-15 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
6,000
0.54
£3,240 		6,000 0.54 £3,240
2019-08-16 2019-08-15 B Purchase
1.8
Charles Sermon

General Counsel
6,355
0.54
£3,400 		6,355 0.54 £3,400
2019-08-15 2019-08-14 B Purchase
1.8
Charles Sermon

General Counsel
754
3.11
£2,341 		754 3.11 £2,341
2019-08-15 2019-08-13 B Purchase
1.8
Charles Sermon

General Counsel
590
3.09
US$1,821 		590 3.09 US$1,821
2019-07-25 2019-07-24 B Purchase Peter Bains

Director

Executive Director
47,500
0.42
£19,950 		47,500 0.42 £19,950
2019-07-19 2019-07-18 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
2,000
2.55
£5,100 		2,000 2.55 £5,100
2019-07-19 2019-07-18 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
8,000
0.45
£3,600 		8,000 0.45 £3,600
2019-07-19 2019-07-17 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
2,000
2.59
£5,180 		2,000 2.59 £5,180
2019-07-19 2019-07-17 B Purchase
1.8
Denise Scots-Knight

Chief Executive Officer

Officer
2,000
0.45
£900 		2,000 0.45 £900
2019-05-23 2019-05-22 B Purchase John Richard

Head of Corporate Development

Officer
3,000
4.90
US$14,709 		3,000 4.90 US$14,709
2019-05-23 2019-05-21 B Purchase Peter Bains

Director

Executive Director
778
4.92
US$3,828 		778 4.92 US$3,828
2019-05-23 2019-05-21 B Purchase Peter Bains

Director

Executive Director
47,500
0.90
£42,750 		47,500 0.90 £42,750
Explore more

More insider trading research around Mereo BioPharma Group PLC

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America